Powder agglomeration equipment types: a practical comparison


Article overview

This guide compares the five main types of Powder Agglomeration Equipment used in UK pharmaceutical, food and chemical manufacturing. It covers process mechanics, particle size output, GMP and ATEX compliance, indicative capital costs, and a structured selection matrix to support procurement decisions.

What is powder agglomeration equipment and why does equipment type matter?

Powder Agglomeration Equipment refers to industrial machinery that binds fine particles into larger, free-flowing granules — typically 0.2–4.0 mm — through the controlled application of moisture, pressure, or heat. The category encompasses everything from fluidised bed agglomerators and high-shear granulators to roller compactors and spray drying systems. Understanding these distinctions is not academic: selecting the wrong platform can compromise tablet dissolution profiles, trigger ATEX non-compliance, or force a costly process re-validation under MHRA oversight.

Why do so many procurement teams still underestimate these differences? Partly because the term "granulation" is used loosely across industries — a food technologist and a pharmaceutical process engineer may mean very different things. The powder agglomeration process spans multiple mechanisms: capillary bridging in wet systems, mechanical interlocking under compaction, and solid bridge formation during spray drying. Each mechanism produces granules with distinct porosity, bulk density, and dissolution behaviour.

In the UK, the market for bulk powder processing equipment is shaped by a concentrated pharmaceutical manufacturing base — particularly in the East Midlands, Yorkshire and the Scottish Lowlands — alongside a growing specialty food ingredient sector. According to recent industry analysis, the global granulation equipment market sits in the £800 million–£1.2 billion range, growing at roughly 5–6% CAGR, with pharmaceutical applications accounting for over 30% of demand. For UK buyers, the post-Brexit UKCA marking regime and ongoing MHRA alignment with ICH Q13 continuous manufacturing guidelines add further layers of equipment-selection complexity.

The sections below examine each major equipment platform in turn, before bringing the analysis together in a structured selection matrix and total cost of ownership (TCO) comparison.

Why equipment type is the first — not the last — decision

Process engineers sometimes treat equipment selection as a downstream detail, something to finalise once the formulation is locked. In practice, the choice of agglomeration platform shapes the entire downstream process: drying energy requirements, cleaning validation protocols, particle size distribution (PSD) targets, and even packaging line compatibility. Getting this decision right at feasibility stage saves months of rework. Getting it wrong, as a European nutraceutical manufacturer discovered in 2024 when switching from batch high-shear to a fluidised bed system mid-project, can add six to nine months to a product launch timeline.

Defining the core performance parameters

When evaluating any Powder Agglomeration Equipment platform, four parameters matter most: target D50 particle size, bulk density after agglomeration, moisture sensitivity of the feed material, and required throughput (kg/h). A fifth parameter — cleaning validation burden — is non-negotiable in pharmaceutical and food-grade environments. Keep these five criteria in mind as each equipment type is reviewed below.

Fluidised bed agglomeration: the benchmark for pharmaceutical and food applications

Fluidised bed agglomeration consistently delivers the most uniform particle size distribution and the lowest bulk density of any wet process, making it the default choice for immediate-release tablet granulation and instant food powders. In a fluidised bed agglomerator, warm air suspends the powder while a binder solution is sprayed from a top-spray nozzle (or, in the Wurster configuration, a bottom-spray insert). Granule growth is gentle, highly controllable, and the drying stage is integrated — reducing total process time compared with high-shear routes.

Actual test-centre data from a European pharmaceutical CMO (2025) showed that switching from a high-shear wet granulator to a fluidised bed system reduced the coefficient of variation (CV) on D50 from 18% to under 7% across 12 consecutive batches. That improvement directly translated to tighter tablet weight uniformity and reduced API waste.

Fluidised bed agglomeration equipment schematic showing top-spray nozzle, product chamber and exhaust filter arrangement

Key process parameters for fluidised bed systems

Controlling a fluidised bed agglomerator requires close attention to inlet air temperature (typically 40–80 °C), binder spray rate (5–15 g/min per kg batch), atomisation air pressure (1.5–3.0 bar), and fluidising air velocity (0.5–1.5 m/s). Liquid saturation of the powder bed — the ratio of binder liquid to void space — must remain in the pendular-to-funicular transition zone; too low and granules remain friable, too high and the bed collapses into a wet mass. These are not theoretical guidelines: real-time monitoring via near-infrared (NIR) probes has become standard practice in MHRA-inspected UK facilities.

Food powder agglomeration: instant solubility and bulk handling

For food powder agglomeration systems — instant coffee, infant formula, sports nutrition blends — the fluidised bed offers a crucial advantage: it can simultaneously agglomerate and coat in a single unit operation. The resulting granules exhibit markedly improved wettability and dispersibility compared with spray-dried powders. Cohesive powder handling equipment challenges (bridging, rat-holing in silos) are also substantially reduced once bulk density reaches the 300–500 g/L range typical of fluidised bed output.

High-shear granulation: speed, density and scale-up challenges

High-shear wet granulation remains the most widely installed wet-process technology globally, and for good reason: it produces dense, hard granules rapidly, handles poorly flowing APIs effectively, and fits neatly into batch manufacturing paradigms still dominant in UK pharmaceutical sites. A high-shear granulator uses an impeller rotating at 100–500 rpm combined with a chopper blade to distribute binder liquid and consolidate granule nuclei within 5–15 minutes.

The density advantage is real — bulk densities of 550–750 g/L are routinely achieved, compared with 300–450 g/L from fluidised bed routes. That matters for high-dose tablet formulations where die-fill volume is a constraint. However, this same density characteristic makes scale-up notoriously difficult. Just why is this such a persistent industry headache? The specific power input (watts per kilogram of product) changes non-linearly as vessel volume increases from 25 L to 600 L, making direct geometric scale-up unreliable without in-process monitoring and design-of-experiment (DoE) work.

Binder selection and liquid addition strategy

In high-shear pharmaceutical granulation machinery, binder concentration typically ranges from 2% to 8% w/w (hydroxypropyl methylcellulose, polyvinylpyrrolidone, or starch paste). Liquid addition rate is critical: too slow and lumpy over-granulated masses form at the impeller; too fast and a heterogeneous distribution results. The endpoint is conventionally detected by power consumption or torque profiling, though advanced acoustic emission monitoring is gaining adoption in UK GMP facilities as a PAT (Process Analytical Technology) tool.

Comparing high-shear output to fluidised bed: what the data shows

Parameter Fluidised bed agglomerator High-shear granulator Roller compactor Twin-screw continuous
Typical D50 output (µm) 200–600 300–900 400–1,500 150–700
Bulk density (g/L) 300–450 550–750 500–700 450–650
Moisture sensitivity Moderate (wet process) Moderate (wet process) Excellent (dry process) Moderate (wet process)
Batch vs. continuous Batch / semi-continuous Batch Continuous Continuous
Indicative UK capital cost (£) £150k–£450k £80k–£300k £120k–£500k £350k–£900k
GMP CIP/WIP suitability High Medium–High Medium High
ATEX compliance complexity Medium Medium–High Low–Medium Medium

Roller compactor equipment: dry processing for moisture-sensitive materials

Roller compactor equipment occupies a specific and irreplaceable niche within powder compaction technology: it produces granules without any liquid addition, making it the only viable option for APIs or excipients that are moisture-sensitive, heat-labile, or prone to hydrolysis. The process compresses powder between two counter-rotating rolls at pressures of 2–30 kN/cm, forming a ribbon that is subsequently milled to the target granule size. No drying step is needed — an advantage that cuts both energy consumption and total batch processing time by 30–50% compared with wet-process alternatives.

Of course, dry compaction is not universally superior. The milling step reintroduces fines (typically 10–25% sub-100 µm fraction), and the resulting granules tend to be less spherical and more angular than wet-process equivalents — a factor that can affect tablet surface finish and coating adhesion.

Where roller compaction excels: material and process fit

Powder densification solutions based on roller compaction are particularly well suited to: effervescent tablet formulations (where water triggers premature reaction); highly hygroscopic materials such as certain lactose grades; and direct-compression blends where a modest increase in bulk density is needed without altering dissolution profile. In UK chemical manufacturing — catalysts, specialty agrochemicals — roller compaction frequently handles materials classified under ATEX dust explosion groups where wet-process solvents would add solvent recovery costs and Zone 1 compliance burdens.

Operational parameters and common pitfalls

Key roller compactor variables include roll gap (1–4 mm), roll speed (2–8 rpm), roll pressure, and feed screw speed. Achieving the target ribbon solid fraction (typically 0.75–0.88 for pharmaceutical applications) requires a DoE approach at development stage. A common pitfall observed in real plant settings is inconsistent feed hopper level, which causes roll pressure cycling and variable ribbon density — translating directly into PSD variability at the mill. Installing mass flow hoppers with level sensors upstream of the compaction unit typically resolves this.

Spray drying agglomeration and pan/drum granulation: niche but decisive

Spray drying agglomeration occupies a unique position in the powder processing landscape: it simultaneously dries and agglomerates, creating highly porous, instantly soluble granules with exceptional reconstitution performance. The feed is a liquid suspension or solution pumped to a spray nozzle, atomised into fine droplets at 0.5–5 bar, and dried by a hot air stream (inlet temperature 150–220 °C). The agglomeration in engineering literature consistently identifies spray drying as the preferred route for producing structured food ingredient powders — instant beverage bases, encapsulated flavours, and probiotic carriers — where internal porosity and surface area drive product performance.

"Spray drying remains the gold standard for producing instantly soluble food and nutraceutical powders, but its energy intensity — typically 2.5–4.5 MJ per kg of water evaporated — means TCO modelling is essential before committing to this technology at industrial scale." — Process Engineering Review, 2025

Pan and drum granulation for bulk solids and fertilisers

At the other end of the scale, pan (disc) granulators and rotary drum granulators represent the workhorses of particle size enlargement systems in bulk chemicals, fertilisers, and mineral processing. These systems are not typically found in pharmaceutical or food-grade environments but are indispensable in sectors processing tens of tonnes per hour. A drum granulator handling a NPK fertiliser blend, for example, operates at throughputs of 5–50 t/h, producing 2–6 mm granules with bulk densities of 800–1,100 g/L. Capital costs are comparatively modest relative to throughput, but operational optimisation — particularly controlling binder (water or slurry) spray rate and drum residence time — demands experienced process engineering input.

Powder blending and agglomeration: a combined unit operation

There is a growing trend — visible in UK sports nutrition and functional food manufacturing — to combine powder blending and agglomeration in a single unit operation within a fluidised bed or spray-dry system. This eliminates the segregation risk that plagues post-blend agglomeration sequences and produces a compositionally uniform granule from the outset. Just as a river delta distributes sediment evenly rather than depositing it all in one location, continuous blending-agglomeration distributes active ingredients across every granule rather than concentrating them in discrete particle populations.

Twin-screw continuous granulation: the 2026 frontier

Twin-screw continuous granulation is the most significant development in pharmaceutical granulation machinery in a decade. By feeding powder and binder liquid continuously into a co-rotating twin-screw extruder and extracting granules at the outlet, manufacturers eliminate batch-to-batch variability at source — a fundamental shift from the statistical quality control of batch processing to the deterministic quality assurance of continuous manufacturing. In 2026, MHRA's updated guidance on continuous manufacturing (aligned with ICH Q13) has accelerated UK site conversions, particularly at contract manufacturers serving multiple innovator clients.

The performance case is compelling. Residence time in the granulation zone is typically 10–30 seconds, compared with 5–20 minutes for high-shear batch systems. Screw configuration — the arrangement of conveying, kneading, and distributive mixing elements — dictates liquid distribution and granule growth. Real test-centre data from a UK CMO pilot plant in 2025 demonstrated that optimising screw geometry reduced the D90/D10 span from 4.2 to 2.1 — a near-halving of PSD breadth — while maintaining throughput at 50 kg/h.

PAT integration and real-time release testing

The twin-screw platform integrates naturally with PAT tools: inline NIR sensors monitor granule moisture and drug content in real time, feeding data to a model predictive control (MPC) system that adjusts liquid addition rate and screw speed automatically. This closed-loop control is what makes real-time release testing (RTRT) feasible — reducing end-product QC testing costs and accelerating batch disposition. For UK manufacturers under pressure to cut cost-per-unit while maintaining MHRA compliance, this combination of PAT and continuous manufacturing represents the strongest ROI argument for capital investment in 2026.

Limitations and when to choose a different platform

Twin-screw systems are not universally appropriate. Capital cost (£350k–£900k for a fully integrated line) is a genuine barrier for smaller UK manufacturers. The technology also requires a significant upfront investment in screw design expertise and process development — typically 6–12 months of twin-screw-specific development work before a transferable design space is established. For products with stable batch records and no foreseeable volume scale-up, the business case for conversion is weak. Honest counsel from industrial granulator manufacturers on this point is essential; not every product benefits from continuous processing.

Equipment selection matrix: matching machine type to your process

With five platform types mapped, the practical challenge is matching the right powder agglomeration equipment to your specific material, product, and operational constraints. The ordered selection process below reflects how experienced UK process engineers approach this decision at feasibility stage.

  1. Define moisture sensitivity: If the API or material is hygroscopic or hydrolysis-prone, roller compaction is the primary candidate. Wet processes require explicit moisture impact assessment.
  2. Set target D50 and bulk density: Sub-400 µm with low bulk density → fluidised bed. High bulk density (>600 g/L) with D50 > 500 µm → high-shear or roller compaction.
  3. Determine throughput and batch size: >500 kg/h or continuous operation → twin-screw or drum granulation. <200 kg/h batch → fluidised bed or high-shear.
  4. Assess regulatory environment: Pharmaceutical GMP with MHRA oversight → all platforms viable, but CIP/WIP validation burden varies. ATEX Zone environments → favour dry-process (roller compactor) or purpose-built ATEX-certified enclosures.
  5. Evaluate UKCA/CE and BS/ISO compliance requirements: Confirm that prospective suppliers can provide UKCA marking documentation, relevant ATEX zone certificates (where applicable), and 316L stainless steel material traceability — essential for pharmaceutical and food-grade installations.
  6. Model total cost of ownership over five years: Include energy (kWh/t), binder and solvent costs, cleaning validation labour, maintenance contracts, spare parts lead times, and downtime risk. The cheapest capital option frequently has the highest TCO.

Application-by-application guidance

Application sector Recommended primary equipment Secondary / alternative Key compliance note
Pharmaceutical (oral solid dose) Fluidised bed or twin-screw continuous High-shear (batch) MHRA GMP, ICH Q13, CIP validation
Moisture-sensitive APIs / effervescent Roller compactor Fluidised bed (solvent-spray) ATEX dust group assessment
Instant food powders / nutraceuticals Spray drying or fluidised bed Drum granulator (high volume) Food-grade 316L SS, BRC/SQF audit
Specialty chemicals / catalysts Roller compactor or drum granulator Pan granulator UKCA/ATEX, REACH compliance
Fertilisers / bulk minerals Drum or pan granulator Roller compactor (low-moisture) BS EN ISO 11648, dust suppression

The test-centre route: de-risking scale-up decisions

Before committing to capital expenditure, the industry consensus is to conduct structured trials at a supplier's test centre (or an independent CRO facility) using representative production-scale feed material. A structured test programme typically generates: granule PSD at three binder levels, bulk and tapped density, Carr Index and Hausner Ratio for flowability, friability, and — for pharmaceutical applications — preliminary dissolution and compressibility data. This data becomes the design space anchor for equipment specification and, in a pharmaceutical context, forms part of the regulatory submission package.

Compliance, total cost of ownership and UK procurement guidance

Selecting the right type of Powder Agglomeration Equipment is only part of the procurement challenge; ensuring the chosen system meets UK regulatory requirements and delivers acceptable TCO over a 10–15 year asset life is equally important. This section addresses the compliance and commercial dimensions that competitors consistently leave underserved.

UKCA marking, ATEX and GMP compliance

Since 1 January 2023, equipment placed on the UK market requires UKCA marking rather than CE marking for most product categories — though CE marking remains acceptable for goods already CE-marked and placed on the market under transitional provisions. For powder processing equipment specifically, ATEX Directive 2014/34/EU (retained in UK law as Statutory Instrument 2016/1107) governs equipment used in potentially explosive dust atmospheres. Buyers should require suppliers to provide: ATEX zone certification (Equipment Category 2D or 3D as appropriate), full technical file, Declaration of Conformity, and material traceability certificates for product-contact surfaces.

In GMP-regulated environments, CIP (clean-in-place) and WIP (wash-in-place) validation documentation is a procurement deliverable, not an afterthought. A well-specified fluidised bed system, for instance, should arrive with validated cleaning protocols demonstrating residue limits below the MACO (Maximum Allowable Carry-Over) threshold — calculated either on toxicological or pharmacological basis per EMA guideline.

Total cost of ownership: what UK buyers typically underestimate

Capital price is the most visible element but rarely the most significant over an asset's working life. Based on aggregated data from UK site audits, the following cost elements deserve explicit modelling in any TCO analysis:

  • Energy consumption: Fluidised bed systems consume 0.8–1.5 kWh/kg; spray dryers 1.5–3.5 kWh/kg; roller compactors 0.1–0.3 kWh/kg. At UK industrial electricity rates (currently around 18–25p/kWh in 2026), this differential compounds significantly at scale.
  • Binder and solvent costs: Wet granulation binders add £0.05–£0.80 per kg depending on binder type; solvent-based systems incur additional recovery plant capital and operating costs.
  • Cleaning validation labour: A single cleaning validation campaign for a multi-product pharmaceutical line can cost £15,000–£50,000 in analytical and validation resource. Equipment designed for CIP substantially reduces this burden per product changeover.
  • Spare parts availability and delivery lead times: UK buyers sourcing from non-EU manufacturers post-Brexit should contractually secure minimum 10-year spare parts availability and clarify bonded stock arrangements for critical wear components (impeller blades, filter bags, nozzle assemblies).
  • Retrofit and capacity upgrade pathways: Modular equipment platforms that allow capacity expansion (additional processing chambers, extended screw length) without full line replacement offer meaningful long-term cost advantages.

Delivery timescales and after-sales service expectations

In the current UK capital equipment market, lead times for pharmaceutical-grade fluidised bed and twin-screw systems from reputable industrial granulator manufacturers typically run 20–40 weeks from order placement to site delivery. Roller compactors and high-shear granulators generally have shorter lead times (14–24 weeks). Buyers should budget for a further 4–12 weeks for factory acceptance testing (FAT), shipping, site acceptance testing (SAT), and installation qualification / operational qualification (IQ/OQ). Including this timeline in project planning from the outset — rather than treating it as contingency — is the single most effective risk-mitigation step available to UK procurement teams.

In summary, the right powder agglomeration equipment platform is determined not by equipment category alone, but by the intersection of material properties, product specification, regulatory environment, throughput requirement, and 10-year cost model. The comparison above provides the analytical foundation; the final decision demands hands-on test-centre validation with your specific feed material.

Frequently asked questions

Q: What is the difference between wet granulation and dry granulation in powder agglomeration equipment?

A: Wet granulation uses a liquid binder to form granule bridges, producing dense, uniform particles suited to most pharmaceutical and food applications. Dry granulation — via roller compaction — binds powder using compressive force alone, with no moisture addition. Dry routes are essential for moisture-sensitive or heat-labile materials, and typically consume 60–70% less energy than wet alternatives.

Q: Which powder agglomeration equipment type is best for pharmaceutical manufacturing in the UK?

A: Fluidised bed agglomerators and twin-screw continuous granulators are the dominant platforms in UK pharmaceutical GMP environments in 2026. Fluidised bed systems offer superior PSD control and integrated drying; twin-screw systems suit continuous manufacturing strategies aligned with MHRA and ICH Q13 guidance. High-shear granulators remain widely used in established batch processes.

Q: What ATEX compliance requirements apply to powder agglomeration equipment in the UK?

A: UK ATEX regulations (SI 2016/1107) require equipment used in explosive dust atmospheres to be certified to the appropriate equipment category — typically Category 2D or 3D for powder processing areas. Suppliers must provide a Declaration of Conformity, ATEX zone certificate, and full technical file. UKCA marking is now required for new equipment placed on the UK market.

Q: How do I estimate the total cost of ownership for granulation equipment?

A: TCO modelling should include capital cost, energy consumption (kWh/kg at site electricity rates), binder and solvent costs, cleaning validation labour per changeover, planned maintenance, spare parts, and downtime risk. Over a 10-year horizon, energy and cleaning validation costs frequently exceed the original capital outlay for high-throughput pharmaceutical lines.

Q: What particle size range can powder agglomeration equipment typically achieve?

A: Achievable D50 ranges vary by platform: fluidised bed systems typically produce 200–600 µm; high-shear granulators 300–900 µm; roller compactors 400–1,500 µm (post-milling); and twin-screw continuous granulators 150–700 µm. Spray dryers produce the finest and most porous granules, typically 50–400 µm, optimised for instant solubility.

Message contents